Phase 3RecruitingAge-related condition
Study on the treatment of weak bones in people with chronic kidney disease
Osteoporosis for Chronic Kidney Disease
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Enrollment
- 160 planned
- Conditions
- Osteoporosis; Bone Diseases, Metabolic Chronic kidney disease, unspecified; N18.9
- Interventions
- This is a prospective, multicenter cohort study with an embedded randomized, double-blind, placebo-controlled clinical trial; Group 2) Patients with normal bone mass and elevated carboxy-terminal telopeptide of type I collagen levels, or low bone mass and suppressed carboxy-terminal telopeptide of type I collagen levels; Group 3) Patients with low bone mass and non-suppressed carboxy-terminal telopeptide of type I collagen levels; 70 mg once weekly) or placebo (n=80; Dilucap SLD excipient, 70 mg once weekly) for 24 months
- Ages
- adults, older adults
- Registry
- RBR-6vph3p2
Full record on ReBECSource: WHO ICTRP, processed October 5, 2026
Primary outcomes
- It is expected that there will be an increase in bone mineral density at the lumbar spine (L1–L4) and/or total femur, measured by densitometry, after 24 months of treatment with alendronate sodium.
History
Study completion expected
Last registry update
Registered
Started